

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FI	LING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
10/716,793	11/18/2003		Debbie Yaver	10351.200-US	8797
25907	7590	01/13/2006		EXAMINER	
NOVOZYMES, INC.			JOIKE, MICHELE K		
1445 DREW DAVIS, CA				ART UNIT PAPER NUMBER	
.,				1636	

DATE MAILED: 01/13/2006

Please find below and/or attached an Office communication concerning this application or proceeding.



UNITED STATES DEPARTMENT OF COMMERCE U.S. Patent and Trademark Office

Address: COMMISSIONER FOR PATENTS

P.O. Box 1450

Alexandria, Virginia 22313-1450

		FIRST NAMED INVENTOR / PATENT IN REEXAMINATION	ATTORNEY DOCKET NO.		
				EXAMINER	
			ART UNIT	PAPER	
				20060105	

DATE MAILED:

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner for Patents

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 CFR 1.821 through 1.825 for the reason(s) set forth below or on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures.

Page 41, line 27, of the Specification and claims 10 and 62 have nucleotide sequences that are greater than ten nucleotides, but have no sequence identifier. These sequences are also not listed in the Sequence Listing.

Applicant is given ONE MONTH, or THIRTY DAYS, whichever is longer, from the mailing date of this letter within which to comply with the sequence rules, 37 CFR 1.821 - 1.825.

Failure to comply with these requirements will result in ABANDONMENT of the application under 37 CFR 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a). In no case may an applicant extend the period for reply beyond the SIX MONTH statutory period.

Direct the reply to the undersigned. Applicant is requested to return a copy of the attached Notice to Comply with the reply.

PRIMARY EXAMINER

Michele K. Joike, Ph.D. AU 1636

	Application No.	Applicant(s)						
Notice to Comply	10/716,793	Yaver et al						
Notice to Comply	Examiner	Art Unit						
	Michele K. Joike, Ph.D.	1636						
NOTICE TO COMPLY WITH REQUIREMENT			INING					
NUCLEOTIDE SEQUENCE AND/OR AMINO	ACID SEQUENCE DISCLO	SURES						
Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).								
The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):								
■ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).								
2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).								
☐ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).								
4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."								
5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).								
☐ 6. The paper copy of the "Sequence Listing" is not the as required by 37 C.F.R. 1.821(e).	ne same as the computer readabl	e from of the "Sec	quence Listing"					
□ 7. Other: Sequences are listed with no sequence identified.	er.							
Applicant Must Provide: ☑ An initial or substitute computer readable form (CRF	c) copy of the "Sequence Listing".							
An initial or substitute paper copy of the "Sequence specification.	Listing", as well as an amendmer	it directing its entr	y into the					
A statement that the content of the paper and comp no new matter, as required by 37 C.F.R. 1.821(e) or 1.8	outer readable copies are the sar 21(f) or 1.821(g) or 1.825(b) or 1.	ne and, where ap 825(d).	plicable, include					
For questions regarding compliance to these requirements, please contact:								
For Rules Interpretation, call (703) 308-4216								
For CRF Submission Help, call (703) 308-4212								
Patentin Software Program Support	702 207 0200							
Technical Assistance To Purchase Patentln Software								

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY